All News
Filter News
Found 808,462 articles
-
Project Aims to Develop Database for Guiding Precision Medicine Treatments
1/25/2016
-
Typing Fast Kills Your Writing Skills, University Of Waterloo Study
1/25/2016
-
TetraLogic Slashes Two-Thirds of Workforce After Mid-Stage Trial Failure
1/25/2016
-
Pharma Giants AstraZeneca PLC, GlaxoSmithKline and Johnson & Johnson Partner Up with UK Universities to Create $57 Million R&D Fund
1/25/2016
-
Oestrogen Supplements May Protect Against Dementia, Norwegian University Of Science And Technology Study
1/25/2016
-
Low Brain Levels of Vitamin B12 in Schizophrenics and Autistic Patients, Nova Southeastern University Researchers Reveal
1/25/2016
-
Mixed Emotions A Sign Of Emotional Depth, Not Indecision, Say University of Waterloo Researchers
1/25/2016
-
Amgen's Vectibix + BSC Meets Primary Endpoint in Phase III Study
1/25/2016
-
FDA Grants Full Approval for Amgen's Blood Cancer Drug
1/25/2016
-
Independent Experts Say Bay Area's OncoMed's Pancreatic Cancer Drug Unlikely to Succeed in Phase II Study
1/25/2016
-
Pfizer Quietly Recalls Three Lots of Blockbuster Drug Lyrica
1/25/2016
-
60 Genetic Disorders Affect Skin And Nervous System, Loyola University Medical Center Study
1/25/2016
-
Kyowa Hakko's Leo R. Cullen Promoted To President And CEO
1/25/2016
-
Zafgen Falls as Hedge Fund Shorts Stock, Claims Obesity Drug Will Not Gain FDA Approval
1/25/2016
-
Johnson & Johnson Halts Trial of Drug Similar to One Linked to Brain Dead Tragedy in France
1/25/2016
-
Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured At The ASCO 2016 Gastrointestinal Cancers Symposium
1/25/2016
-
Celgene Release: Data Presented At ASCO GI Highlight The Feasibility Of Second-Line Treatment In Patients With Metastatic Pancreatic Cancer Who Have Received First-Line Abraxane Plus Gemcitabine
1/25/2016
-
Cytori Therapeutics, Inc. Update On Its U.S. Phase III Scleroderma Trial
1/25/2016
-
Why Genome-Sequencing Pioneer Morphed From Science God To Punching Bag
1/25/2016
-
Ixchelsis Ltd Announces Positive Clinical Proof Of Concept Results For IX-01 In Treating Premature Ejaculation
1/25/2016